Ocular Therapeutix, Inc.

OTX-TKI(axitinib intravitreal implant)

SUSTAINED-RELEASE PRODUCT CANDIDATE FOR RETINAL DISEASES

OTX-TKI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule tyrosine kinase inhibitor with anti-angiogenic properties being evaluated for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases.¹

EXISTING TREATMENTS

Require intravitreal injections every 4-8 weeks^2,3

May cause endophthalmitis, ocular hemorrhage, damage to the lens or retinal detachment due to repeated injections^4,5

May cause discomfort, eye pain, vision blurred,³ and floaters^3,6

PRODUCT CANDIDATE ATTRIBUTES

Targeting sustained release for 6 months or longer¹

Broad anti-angiogenic profile (small molecule)¹

Small fiber with minimal/no visual impact⁷

Preservative-free¹